Clinical trials: Optic Neuropathy, Anterior Ischemic
Anterior Ischemic Optic Neuropathy
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
The primary objective of this study is to determine whether the use of PDE5 inhibitors (vardenafil, sildenafil, or tadalafil) increases the risk for the development of NAION.
- Trial name
- NCT00867815
- Testing
- Diagnostic procedures
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Bayer
Non-Arteritic Anterior Ischemic Optic Neuropathy
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION.
- Trial name
- NCT07453888
- Testing
- Cenegermin, Vehicle
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 272 people
- Sponsor
- Dompé Farmaceutici S.p.A
Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic…
- Trial name
- NCT07290244
- Testing
- ER-100 epigenetic therapy
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Life Biosciences Inc.
Retinitis Pigmentosa, Macula Off
Transcorneal Electrical Stimulation Therapy for Retinal Disease
Transcorneal stimulation may enable neurons to survive degeneration processes via enhanced secretion of neurotrophic substances and direct stimulation of neurons.
- Conditions
- Retinitis Pigmentosa, Macula Off, Primary Open Angle Glaucoma, Hereditary Macular Degeneration
- Trial name
- NCT00804102
- Testing
- Transcorneal Electrical Stimulation, DTL-electrode attached without energy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Okuvision GmbH
Non Arteritic Anterior Ischemic Optic Neuropathy
Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and tolerability of intravitreal injections of QPI-1007 in this population.
- Trial name
- NCT02341560
- Testing
- QPI-1007 Injection - 1.5 mg, QPI-1007 Injection - 3.0 mg
- Where
- 85 sites in United States, Australia and 6 more
- Volunteers
- 732 people
- Sponsor
- Quark Pharmaceuticals
Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
This is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (QPI-1007) will be given to all patients who participate.
- Trial name
- NCT01064505
- Testing
- QPI-1007 at various doses
- Where
- 28 sites in United States, Israel
- Volunteers
- 48 people
- Sponsor
- Quark Pharmaceuticals
Nonarteritic Anterior Ischemic Optic Neuropathy
Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
This study is designed as a double-masked, randomized, placebo-controlled, clinical study to evaluate the efficacy and safety of subcutaneous (SC) administration of RPh201 in participants with previous NAION.
- Trial name
- NCT03547206
- Testing
- RPh201 Cohort A, RPh201 Cohort B
- Where
- 15 sites in United States
- Volunteers
- 165 people
- Sponsor
- Regenera Pharma Ltd
Anterior Ischemic Optic Neuropathy, Ischemic Optic Neuropathy
Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
The objectives of this study were to: (1) evaluate the natural history of non-arteritic anterior ischemic optic neuropathy (NAION); (2) estimate the population incidence of NAION; and (3) identify potential risk factors for NAION.
- Trial name
- NCT01260324
- Testing
- No intervention given in this observational study
- Volunteers
- 21,283 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Nonarteritic Anterior Ischemic Optic Neuropathy
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
Study H6D-MC-LVHQ is an observational, non-interventional, multi-center, prospective, case-crossover study to evaluate the possible association between the use of phosphodiesterase type 5 (PDE5) inhibitors and the risk of acute…
- Trial name
- NCT01131104
- Testing
- PDE5 Inhibitors
- Where
- 44 sites in United States
- Volunteers
- 345 people
- Sponsor
- Eli Lilly and Company